Company Overview: Matinas BioPharma Holdings

Industry News

30 Mar

Matinas BioPharma Completes Enrollment in First Human Trial of MAT9001

Matinas BioPharma Holdings, Inc.(“Matinas BioPharma” or the “Company”) (MTNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of lipid-based prescription therapeutics for the treatment of infectious diseases and cardiovascular and metabolic conditions, today announced that upon a scheduled interim review, the study’s Steering Committee recommended to stop...

Read more

5 Feb

Matinas BioPharma to Present at the 17th Annual BIO CEO & Investor Conference on February 9, 2015

Live Webcast on Monday, February 9, 2015, at 4:00 p.m. EST Matinas BioPharma Holdings, Inc.(“Matinas BioPharma” or the “Company”) (MTNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of lipid-based prescription therapeutics for the treatment of metabolic and cardiovascular conditions and the treatment of infectious diseases, announced...

Read more

4 Nov

Matinas BioPharma Appoints Cardiologist and Lipidology Expert Christie M. Ballantyne, M.D. to Scientific Advisory Board

Matinas BioPharma Holdings, Inc.(“Matinas BioPharma” or the “Company”) (MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions, today announced that it has established a new Scientific Advisory Board (SAB) and appointed internationally renowned...

Read more

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address